166 related articles for article (PubMed ID: 37801341)
21. Generation of Monkey Induced Pluripotent Stem Cell-Derived Cartilage Lacking Major Histocompatibility Complex Class I Molecules on the Cell Surface.
Okutani Y; Abe K; Yamashita A; Morioka M; Matsuda S; Tsumaki N
Tissue Eng Part A; 2022 Jan; 28(1-2):94-106. PubMed ID: 34182799
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic control of
Wang MM; Koskela SA; Mehmood A; Langguth M; Maranou E; Figueiredo CR
Front Immunol; 2023; 14():1152228. PubMed ID: 37077920
[TBL] [Abstract][Full Text] [Related]
23. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
24. Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells.
Wang D; Quan Y; Yan Q; Morales JE; Wetsel RA
Stem Cells Transl Med; 2015 Oct; 4(10):1234-45. PubMed ID: 26285657
[TBL] [Abstract][Full Text] [Related]
25. Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post-PD-1 Immunotherapy.
Nielsen M; Presti M; Sztupinszki Z; Jensen AWP; Draghi A; Chamberlain CA; Schina A; Yde CW; Wojcik J; Szallasi Z; Crowther MD; Svane IM; Donia M
Cancer Immunol Res; 2022 Oct; 10(10):1254-1262. PubMed ID: 35969233
[TBL] [Abstract][Full Text] [Related]
26. Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T cells from allogeneic NK cell-mediated lysis.
Guo Y; Xu B; Wu Z; Bo J; Tong C; Chen D; Wang J; Wang H; Wang Y; Han W
Eur J Immunol; 2021 Oct; 51(10):2513-2521. PubMed ID: 34323289
[TBL] [Abstract][Full Text] [Related]
27. Characterization of MHC Class I and β-2-Microglobulin Expression in Pediatric Solid Malignancies to Guide Selection of Immune-Based Therapeutic Trials.
Haworth KB; Arnold MA; Pierson CR; Leddon JL; Kurmashev DK; Swain HM; Hutzen BJ; Roberts RD; Cripe TP
Pediatr Blood Cancer; 2016 Apr; 63(4):618-26. PubMed ID: 26575538
[TBL] [Abstract][Full Text] [Related]
28. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.
Homet Moreno B; Zaretsky JM; Garcia-Diaz A; Tsoi J; Parisi G; Robert L; Meeth K; Ndoye A; Bosenberg M; Weeraratna AT; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Ribas A
Cancer Immunol Res; 2016 Oct; 4(10):845-857. PubMed ID: 27589875
[TBL] [Abstract][Full Text] [Related]
29. Uncoupling CD4+ TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma.
Draghi A; Presti M; Jensen AWP; Chamberlain CA; Albieri B; Rasmussen AK; Andersen MH; Crowther MD; Svane IM; Donia M
Clin Cancer Res; 2023 Oct; 29(19):3937-3947. PubMed ID: 37126006
[TBL] [Abstract][Full Text] [Related]
30. Long-lasting mRNA-encoded interleukin-2 restores CD8
Beck JD; Diken M; Suchan M; Streuber M; Diken E; Kolb L; Allnoch L; Vascotto F; Peters D; Beißert T; Akilli-Öztürk Ö; Türeci Ö; Kreiter S; Vormehr M; Sahin U
Cancer Cell; 2024 Apr; 42(4):568-582.e11. PubMed ID: 38490213
[TBL] [Abstract][Full Text] [Related]
31. B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy.
Zhao Y; Cao Y; Chen Y; Wu L; Hang H; Jiang C; Zhou X
Immunology; 2021 Nov; 164(3):507-523. PubMed ID: 34115389
[TBL] [Abstract][Full Text] [Related]
32. Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene.
Maio M; Altomonte M; Tatake R; Zeff RA; Ferrone S
J Clin Invest; 1991 Jul; 88(1):282-9. PubMed ID: 1905328
[TBL] [Abstract][Full Text] [Related]
33. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
Front Immunol; 2022; 13():794684. PubMed ID: 35720386
[TBL] [Abstract][Full Text] [Related]
34. Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8
Hutmacher C; Gonzalo Núñez N; Liuzzi AR; Becher B; Neri D
Cancer Immunol Res; 2019 Apr; 7(4):572-583. PubMed ID: 30782667
[TBL] [Abstract][Full Text] [Related]
35. Anti-PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression.
Tritz ZP; Ayasoufi K; Wolf DM; Owens CA; Malo CS; Himes BT; Fain CE; Goddery EN; Yokanovich LT; Jin F; Hansen MJ; Parney IF; Wang C; Moynihan KD; Irvine DJ; Wittrup KD; Diaz Marcano RM; Vile RG; Johnson AJ
Cancer Immunol Res; 2023 Jun; 11(6):763-776. PubMed ID: 36921098
[TBL] [Abstract][Full Text] [Related]
36. Combination of PD-1 Checkpoint Blockade and Botulinum Toxin Type A1 Improves Antitumor Responses in Mouse Tumor Models of Melanoma and Colon Carcinoma.
Kwak S; Lee JY; Kim MJ; Lee HJ; Lee DK; Kang J; Kang WH; Son WC; Cruz DJM
Immunol Invest; 2023 Nov; 52(6):749-766. PubMed ID: 37403798
[TBL] [Abstract][Full Text] [Related]
37. Triple (GGTA1, CMAH, B2M) modified pigs expressing an SLA class I
Hein R; Sake HJ; Pokoyski C; Hundrieser J; Brinkmann A; Baars W; Nowak-Imialek M; Lucas-Hahn A; Figueiredo C; Schuberth HJ; Niemann H; Petersen B; Schwinzer R
Am J Transplant; 2020 Apr; 20(4):988-998. PubMed ID: 31733031
[TBL] [Abstract][Full Text] [Related]
38. IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation.
Caudana P; Núñez NG; De La Rochere P; Pinto A; Denizeau J; Alonso R; Niborski LL; Lantz O; Sedlik C; Piaggio E
Cancer Immunol Res; 2019 Mar; 7(3):443-457. PubMed ID: 30651291
[TBL] [Abstract][Full Text] [Related]
39. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
40. Donor Lymphocyte-Derived Natural Killer Cells Control MHC Class I-Negative Melanoma.
Dang N; Lin Y; Waer M; Sprangers B
Cancer Immunol Res; 2020 Jun; 8(6):756-768. PubMed ID: 32209636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
